Abstract

Malaria remains a major global public health challenge, with an estimated 247 million cases and 619,000 deaths in 
2021, predominantly affecting children in sub-Saharan Africa. Efforts to develop an effective malaria vaccine have 
spanned over a century, with significant progress achieved in the last two decades. Vaccines such as RTS, S/AS01 
(Mosquirix®), PfSPZ Vaccine, and R21/Matrix-M target different stages of the Plasmodium life cycle, including 
pre-erythrocytic, erythrocytic, and transmission stages. Despite advances, achieving high and durable efficacy has 
been hampered by the complex parasite life cycle, antigenic variation, and immunological challenges. Clinical trials 
have demonstrated modest protective efficacy, with generally favorable safety profiles. Ongoing research 
emphasizes novel vaccine platforms, combination vaccines, adjuvant optimization, and strategies to enhance 
immune responses across multiple parasite stages. Public-private partnerships, ethical oversight, community 
engagement, and robust regulatory frameworks remain critical to ensuring equitable access and successful 
implementation. Continued innovation in vaccine design and delivery is essential to reduce malaria morbidity and 
mortality and to advance global malaria eradication efforts.